Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06779851 · ClinicalTrials.gov registry record · Phase 1

A Study to Evaluate Safety and Tolerability of BPT567 in Patients With Advanced Solid Tumors

A Phase 1 study of Advanced Solid Tumors, sponsored by Bright Peak Therapeutics.

Active
Registry status
Phase 1
Development phase
100
Enrollment target
7
Study locations

NCT06779851 is a Phase 1 study of Advanced Solid Tumors that is active but no longer recruiting, run by Bright Peak Therapeutics. The registered enrollment target is 100 participants, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (49% lower). The trial reports 7 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06779851, a Phase 1 study of Advanced Solid Tumors, is active but no longer recruiting, sponsored by Bright Peak Therapeutics.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
100 participants
Enrollment target
7
Study locations

Study Summary

This is a first-in-human Phase Ia/Ib, open-label, multicenter, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and maximum tolerated dose (MTD) or maximum adminstered dose (MAD) of BPT567 in patients with advanced solid tumors, and establish the recommended dose for expansion cohorts.

Conditions Studied

Advanced Solid Tumors

Interventions

  • DRUG BPT567

Study Locations (7)

Arizona

  • Honor Health Research Institute - Scottsdale

Michigan

  • Start Midwest - Grand Rapids

New Jersey

  • Hackensack Meridian John Theurer Cancer Center - Hackensack

North Carolina

  • Carolina BioOncology Institute - Huntersville

Oregon

  • Providence Cancer Institute - Portland

Pennsylvania

  • University of Pittsburgh Medical Center - Pittsburgh

Texas

  • South Texas Accelerated Research Therapeutics (START) - San Antonio

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2024-10-15
Est. Completion 2028-12-31
Phase Phase 1

Sponsor

Bright Peak Therapeutics

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06779851

The ClinicalTrials.gov registry entry for NCT06779851 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (49% lower). The listed sponsor is Bright Peak Therapeutics, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Advanced Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which BPT567 is the first listed.

NCT06779851 reports 7 study locations spanning 7 distinct geographic areas - top geographies include Arizona, Michigan, New Jersey.

Frequently Asked Questions

What is clinical trial NCT06779851 about?

NCT06779851 is a clinical study titled "A Study to Evaluate Safety and Tolerability of BPT567 in Patients With Advanced Solid Tumors". This is a first-in-human Phase Ia/Ib, open-label, multicenter, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and maximum tolerated dose (MTD) or maximum adminstered dose (MAD) of BPT567 in patients with advanced ...

What is the current status of trial NCT06779851?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 100 participants. The study started on 2024-10-15. Estimated completion is 2028-12-31.

What conditions does trial NCT06779851 study?

This clinical trial studies the following conditions: Advanced Solid Tumors.

What interventions are being tested in trial NCT06779851?

The interventions under investigation include: BPT567 (DRUG).

Who is sponsoring clinical trial NCT06779851?

This trial is sponsored by Bright Peak Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06779851 being conducted?

This trial has 7 study locations across Arizona, Michigan, New Jersey, North Carolina, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Solid Tumors

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.